All In Biotech

Drug Trial Radar · NCT06710847

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)

Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

14

Actual

Start

Dec 13, 2024

Primary completion

Jun 22, 2026

Study completion Jun 22, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IDEAYA Biosciences
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.

Conditions

  • Neoplasms, Colorectal
  • Solid Tumor
  • Colon Cancer
  • Rectal Cancer
  • Endometrial Cancer

Interventions

  • GSK4418959Drug

    GSK4418959 will be administered.

  • PD-1 inhibitorBiological

    PD-1 inhibitor will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants with dose limiting toxicities (DLTs) during DLT observation periodTime frame: Up to 21 days
  2. Part 3: Number of participants with dose limiting toxicities (DLTs) during DLT observation periodTime frame: Up to 21 days
  3. Part 1: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation periodTime frame: Up to 21 days
  4. Part 3: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation periodTime frame: Up to 21 days
  5. Part 1: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation periodTime frame: Up to 21 days
  6. Part 3: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation periodTime frame: Up to 21 days
  7. Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 26 months

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Shizuoka, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Daegu, South Korea

  • GSK Investigational Site

    Gyeonggi-do, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Málaga, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.